产品概述
产品名称(Product Name) | FGFR3 (Phospho-Tyr724) Rabbit Polyclonal Antibody |
描述(Description) | Rabbit Polyclonal Antibody |
宿主(Host) | Rabbit |
应用(Application) | WB |
种属反应性(Reactivity) | Human,Mouse,Rat |
产品性能
偶联物(Conjugation) | Unconjugated |
修饰(Modification) | Phospho Antibody |
同种型(Isotype) | IgG |
克隆(Clonality) | Polyclonal |
形式(Form) | Liquid |
存放说明(Storage) | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
储存溶液(Buffer) | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N. |
纯化方式(Purification) | Affinity purification |
免疫原
基因名(Gene Name) | FGFR3 JTK4 |
别名(Alternative Names) | Fibroblast growth factor receptor 3 (FGFR-3) (EC 2.7.10.1) (CD antigen CD333) |
基因ID(Gene ID) | 2261 |
蛋白ID(SwissProt ID) | P22607 |
产品应用
稀释比(Dilution Ratio) | WB 1:500-2000 |
蛋白分子量(Molecular Weight) | 89kDa |
研究背景
catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,disease:A chromosomal aberration involving FGFR3 may be a cause of multiple myeloma (MM) [MIM:254500]. Translocation t(4;14)(p16.3;q32.3) with the IgH locus.,disease:Defects in FGFR3 are a cause of bladder cancer [MIM:109800]. Somatic mutations can constitutively activate FGFR3.,disease:Defects in FGFR3 are a cause of cervical cancer [MIM:603956].,disease:Defects in FGFR3 are a cause of hypochondroplasia (HCH) [MIM:146000]. HCH is an autosomal dominant disease and is characterized by disproportionate short stature. It resembles achondroplasia, but with a less severe phenotype.,disease:Defects in FGFR3 are a cause of keratinocytic non-epidermolytic nevus [MIM:162900]; also called pigmented moles. Epidermal nevi of the common, non-organoid and non-epidermolytic type are benign skin lesions and may vary in their extent from a single (usually linear) lesion to widespread and systematized involvement. They may be present at birth or develop early during childhood.,disease:Defects in FGFR3 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:149730]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.,disease:Defects in FGFR3 are a cause of Muenke syndrome (MNKS) [MIM:602849]; also known as Muenke non-syndromic coronal craniosynostosis. MNKS is a condition characterized by premature closure of coronal suture of skull during development (coronal craniosynostosis), which affects the shape of the head and face. It may be uni- or bilateral. When bilateral, it is characterized by a skull with a small antero-posterior diameter (brachycephaly), often with a decrease in the depth of the orbits and hypoplasia of the maxillae. Unilateral closure of the coronal sutures leads to flattening of the orbit on the involved side (plagiocephaly). The intellect is normal. In addition to coronal craniosynostosis some affected individuals show skeletal abnormalities of hands and feet, sensorineural hearing loss, mental retardation and respiratory insufficiency.,disease:Defects in FGFR3 are a cause of thanatophoric dysplasia (TD) [MIM:187600, 187601]; also known as thanatophoric dwarfism. TD is the most common neonatal lethal skeletal dysplasia. Affected individuals display features similar to those seen in homozygous achondroplasia. It causes severe shortening of the limbs with macrocephaly, narrow thorax and short ribs. In the most common subtype, TD1, femur are curved, while in TD2, straight femurs are associated with cloverleaf skull. Mutations affecting different functional domains of FGFR3 cause different forms of this lethal disorder.,disease:Defects in FGFR3 are the cause of achondroplasia (ACH) [MIM:100800]. ACH is an autosomal dominant disease and is the most frequent form of short-limb dwarfism. It is characterized by a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands.,disease:Defects in FGFR3 are the cause of camptodactyly tall stature and hearing loss syndrome (CATSHL syndrome) [MIM:610474]. CATSHL syndrome is an autosomal dominant syndrome characterized by permanent and irreducible flexion of one or more fingers of the hand and/or feet, tall stature, scoliosis and/or a pectus excavatum, and hearing loss. Affected individuals have developmental delay and/or mental retardation, and several of these have microcephaly. Radiographic findings included tall vertebral bodies with irregular borders and broad femoral metaphyses with long tubular shafts. On audiological exam, each tested member have bilateral sensorineural hearing loss and absent otoacoustic emissions. The hearing loss was congenital or developed in early infancy, progressed variably in early childhood, and range from mild to severe. Computed tomography and magnetic resonance imaging reveal that the brain, middle ear, and inner ear are structurally normal.,disease:Defects in FGFR3 are the cause of Crouzon syndrome with acanthosis nigricans (CAN) [MIM:612247]. Classic Crouzon disease which is caused by mutations in the FGFR2 gene is characterized by craniosynostosis (premature fusion of the skull sutures), and facial hypoplasia. Crouzon syndrome with acanthosis nigricans (a skin disorder characterized by pigmentation anomalies), CAN, is considered to be an independant disorder from classic Crouzon syndrome. CAN is characterized by additional more severe physical manifestation, such as Chiari malformation, hydrocephalus, and atresia or stenosis of the choanas, and is caused by a specific mutation (Ala-391 to Glu) in the transmembrane domain of FGFR3. It is proposed to have an autosonal dominant mode of inheritance.,disease:Defects in FGFR3 are the cause of platyspondylic lethal skeletal dysplasia Sand Diego type (PLSD-SD) [MIM:270230]. Platyspondylic lethal skeletal dysplasias (PLSDs) are a heterogeneous group of chondrodysplasias characterized by severe platyspondyly and limb shortening. PLSD-SD is characterized by postnatal growth deficiency, mild developmental delay, short trunk, craniofacial abnormalities, platyspondyly, delayed ossification, generalized osteoporosis and thin ribs.,function:Receptor for acidic and basic fibroblast growth factors. Preferentially binds FGF1.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.,similarity:Contains 1 protein kinase domain.,similarity:Contains 3 Ig-like C2-type (immunoglobulin-like) domains.,tissue specificity:Expressed in brain, kidney and testis. Very low or no expression in spleen, heart, and muscle. In 20- to 22-week old fetuses it is expressed at high level in kidney, lung, small intestine and brain, and to a lower degree in spleen, liver, and muscle. Epithelial cells show exclusively isoform 2 transcripts while fibroblastic cells show a mixture of isoform 1 and isoform 2.,
研究领域
关键字: FGFR3 JTK4;FGFR3;(Phospho-Tyr724);Rabbit;Polyclonal;Antibody;一抗
武汉恩玑生命科技有限公司(EnkiLife)是一家深耕生命科学,专注细胞生物学和免疫学科研试剂的研发、生产与销售的生物技术企业,在全球100多个国家和地区开展业务,致力于为科研工作者提供高质量的产品和卓越的客户服务,推动生命科学的发展。
EnkiLife的产品线涵盖细胞系、原代细胞、细胞培养基、血清、细胞检测试剂盒、重组靶点蛋白、细胞因子、重组抗体、ELISA试剂盒、生化试剂盒等,并提供技术服务与定制开发,覆盖了生命科学研究的各大关键领域,包括细胞生物学、癌症、免疫学、神经科学、心血管疾病、干细胞、表观遗传学、内分泌、蛋白质组学、代谢组学等,全方位满足您的实验需求,让您享受科研的乐趣!
公司现已建立四大技术平台:
EnCyto?细胞培养及检测平台:拥有细胞系库(500+)、原代细胞库(500+)、基础培养基和完全培养基(1200+)
EnkiPro?重组蛋白平台:现货产品2000+,可提供定制化表达服务
EnAb?重组抗体平台:重组兔单抗(3000+),可提供定制化和标记服务
EnKits?试剂盒开发平台:可提供优质的ELISA试剂盒、配套试剂、抗体对、生化试剂盒等相关产品
EnkiLife在生产管理方面引入ISO9001质量管理体系和信息化、自动化的管理工具,拥有高效稳定的交付能力,与全球知名品牌建立了紧密的合作。
EnkiLife始终坚持以技术创新为驱动,以匠心铸就品质,以品质服务客户。
我们期待与更多的全球科研工作者和企业携手合作,共同推动生命科学领域的进步与发展。